A groundbreaking clinical trial aims to investigate the efficacy of a novel neurofeedback device for individuals experiencing recurrent pregnancy loss (RPL) and anxiety. Sponsored by Shenyang Medical College and its affiliated Central Hospital, the study will evaluate closed-loop neurofeedback interventions using a device targeting the right dorsolateral prefrontal cortex (DLPFC). Although the trial is not yet recruiting, it represents a significant step forward in leveraging neurofeedback technology to tackle complex medical conditions.
In this article:
- What is the focus of this study?
- How does the neurofeedback device work?
- What are the potential impacts?
- FAQ
- Conclusion
- Disclaimer
- Source Information
What is the focus of this study?
The clinical trial assesses whether closed-loop neurofeedback technology can enhance autonomic and anxiety regulation in people with recurrent pregnancy loss. Investigators are exploring how changes in brain function can influence physical and psychological outcomes. RPL is a distressing condition, often accompanied by heightened anxiety, which underscores the necessity of innovative medical solutions like this device.
How does the neurofeedback device work?
The trial uses a functional near-infrared spectroscopy (fNIRS)-based brain-computer interface (BCI) neurofeedback system. This advanced device is designed to regulate neural activity in the right dorsolateral prefrontal cortex (DLPFC), a brain region associated with anxiety control and executive functions. Two intervention arms will be tested:
- Real feedback arm: Participants receive real-time neurofeedback to modulate DLPFC activity.
- Sham feedback arm: A control group will receive simulated feedback, providing a comparison for therapeutic outcomes.
The safety and performance of the device will be evaluated in compliance with applicable medical device regulations.
What are the potential impacts?
If successful, this study could pave the way for novel therapeutic tools targeting mental health conditions and physiological disorders, particularly for women facing challenges related to RPL. The closed-loop feedback mechanism holds promise for personalized medical interventions, potentially improving patients’ quality of life and expanding the applications of neurofeedback technology in clinical settings.
FAQ
- What conditions does the study address?
The study focuses on recurrent pregnancy loss and anxiety. - What is the primary intervention device?
The intervention involves an fNIRS-BCI system designed for closed-loop neurofeedback in the right DLPFC region. - Who is conducting the study?
The study sponsors include Shenyang Medical College and the Central Hospital Affiliated to Shenyang Medical College. - When will the trial recruit participants?
As of now, the trial is listed as “Not yet recruiting.” - Where can more information be found?
Details are available on ClinicalTrials.gov at the provided link below.
Conclusion
This clinical trial is a forward-thinking initiative aimed at addressing complex health challenges through advanced neurofeedback technologies. Professionals in clinical research and device regulation should monitor this project closely to understand its outcomes and regulatory approaches. It may set new standards for integrating brain-computer interface solutions into medical practice.
Disclaimer
This article is intended for informational purposes only and does not constitute legal or clinical advice. Always consult regulatory guidelines or professional expertise for actionable advice.
Source Information
For full information about the announcement, see the link below.
https://clinicaltrials.gov/study/NCT07325370?term=medical+device